Vaccitech (VACC) Competitors

scPharmaceuticals (NASDAQ:SCPH) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Which has more risk and volatility, SCPH or VACC?

scPharmaceuticals has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500.

Do analysts rate SCPH or VACC?

scPharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 333.53%. Given scPharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe scPharmaceuticals is more favorable than Vaccitech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vaccitech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to SCPH or VACC?

In the previous week, scPharmaceuticals had 11 more articles in the media than Vaccitech. MarketBeat recorded 12 mentions for scPharmaceuticals and 1 mentions for Vaccitech. scPharmaceuticals' average media sentiment score of 0.15 beat Vaccitech's score of 0.00 indicating that scPharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
scPharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaccitech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, SCPH or VACC?

Vaccitech has lower revenue, but higher earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
scPharmaceuticals	$13.59M	12.74	-$54.81M	-$1.90	-1.82
Vaccitech	$13.42M	2.79	$5.34M	-$1.43	-0.68

Does the MarketBeat Community believe in SCPH or VACC?

scPharmaceuticals received 143 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 66.67% of users gave scPharmaceuticals an outperform vote.

Company	Underperform	Outperform
scPharmaceuticals	Outperform Votes 160 66.67%	Underperform Votes 80 33.33%
Vaccitech	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%

Is SCPH or VACC more profitable?

scPharmaceuticals has a net margin of -264.60% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat scPharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
scPharmaceuticals	-264.60%	-263.11%	-78.40%
Vaccitech	-409.18%	-23.41%	-20.85%

Do insiders and institutionals have more ownership in SCPH or VACC?

89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Vaccitech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

scPharmaceuticals beats Vaccitech on 11 of the 18 factors compared between the two stocks.